no metadatahttps://benchmarkantibodies.com/product/amplicube-coronavirus-panel-rt-pcr-test-mikrogen-50142/
Skip to content

Coronavirus Panel RT-PCR test Mikrogen 50142

$487.00

Summary

  • Mikrogen diagnostik RT PCR kit for research use (RUO)
  • Direct SARS-CoV-2, Coronavirus, MERS-CoV detection
  • High sensitivity and specificity
  • Internal control for monitoring nucleic acid extraction
    (RNA/DNA) and real-time PCR inhibition in each reaction
  • Compatible with most common real-time PCR cyclers & RNA/DNA extraction methods
  • 96 tests
SKU: 50142 Category: Tag:
Weight 1 lbs
Dimensions 9 × 5 × 2 in
target

Coronavirus

species reactivity

For detection of Middle East Respiratory Syndrome Coronavirus (MERS CoV, SARS coronaviruses (incl. SARS-CoV-2 / COVID 19), human coronaviruses (NL63, OC43, 229E, HKU).

applications

RT PCR

assay type

direct & qualitative

available sizes

96 tests

Coronavirus Panel RT-PCR test Mikrogen 50142

kit
Assay type
RT PCR
Research area
Infectious Disease
Sample type
whole blood, serum, plasma, urine, tissue, stool, etc., food and environmental samples or from the carrier material
Notes
Mic (Magnetic Induction Cycler) validated
Roche LightCycler(c) 480 Instrument II validated
Roche covas z 480 Analyzer validated
Qiagen Rotor-Gene(c) Q validated
Bio-Rad CFX 96 validated
Applied Biosystems (QuantStudio TM 5 Dx) validated
Stratagene Mx3000P compatible
Components
Reaction Mix Cap color - yellow 2 x 768 µl
Positive Control Cap color - red 1 x 100 µl
Negative Control Cap color - green 1 x 100 µl
Control DNA Cap color - colorless 2 x 240 µl
Instructions for Use 1 Each
Storage
Store at -20°C.
Additional information

Highly sensitive and specific direct detection of pathogens that can cause tick-borne infections Applicable to human starting material as well as RNA/DNA from the tick

Complete PCR kits with ready-to-use reagents

Compatible with common real-time PCR cyclers Compatible with various RNA/DNA extraction methods (e.g. Mikrogen alphaClean Mag RNA/DNA Kits)

target relevance
Organism
SARS-CoV-2
Structure and strains
SARS-CoV-2 consists of 4 structural proteins and 16 non-structural proteins. The 4 structural proteins are spike (S), envelope (E), nucleocapsid (N) and membrane (M) protein. The N protein is associated with the RNA genome, the S, E and M proteins together form the virus envelope. The S protein is a glycoprotein consisting of two domains, the S1 domain, which contains the receptor binding domain (RBD) responsible for the virus being able to attach to and fuse with the ACE2 receptor of the host cell, and the S2 domain including transmembrane and endodomain. On the virus surface, the S protein forms trimeric structures. N and S protein are major immunogenic proteins of the virus family Coronaviridae and are very well suited for serological detection of anti-SARS-CoV-2 antibodies. Recombinant versions of both proteins are already widely used in different test systems.
Disease
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a strain of coronavirus that causes COVID-19, the respiratory illness responsible for the COVID-19 pandemic. The virus previously had the provisional name 2019 novel coronavirus (2019-nCoV),and has also been called human coronavirus 2019 (HCoV-19 or hCoV-19). SARS-CoV-2 is a positive-sense single-stranded RNA virus that is contagious in humans.
Detection and diagnosis
Neutralizing antibodies during host immune responses are predominantly directed against S protein, which is supposedly suitable for very specific test settings as it is less conserved within the family of Coronaviridae than the other immunogenic antigens. However, recent studies have shown that antibodies against N protein are detectable earlier in mild infections than antibodies directed against S protein. As an acute marker in particular, it can be beneficial to use N protein for most sensitive early detection. In the further course of the immune response, the N protein antibody level decreases, whereas antibodies against S protein are detectable for a longer time. Various studies show that anti-SARS-CoV-2 antibodies of the IgA and IgM class are detectable in the median at the earliest from about six days after the onset of symptoms, increase in the further course of the disease and decrease again between 18 and 35 days. Antibodies of the IgG class are detectable in the median ten to eighteen days after onset of symptoms and are detectable over several months.

Data

No results found

Publications

Publications

pmid title authors citation
We haven't added any publications to our database yet.
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.

Protocols

relevant to this product
50142 protocol

Documents

#
Please enter your product and batch number here to retrieve product datasheet, SDS, and QC information.